Cancer Archives

News and Trends 3 Jun 2015

Erytech successfully completed its Phase III to ‘starve’ cancer cells to death

Erytech Pharma reported optimistic Phase III results of its pivotal program with GRASPA, an original treatment that targets cancer cells through “tumor starvation”. The positive results were presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO). Erytech Pharma’s technology makes it possible to “starve” cancer cells by depriving them of […]

June 3, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 2 Jun 2015

Genticel aims to prevent Cancer caused by the Human Papillomavirus

Genticel is a step closer to prevent cancer caused by the human papillomavirus (HPV). The French biotech announced positive results of GTL002’s preclinical in vivo proof of concept, Genticel’s multivalent HPV therapeutic vaccine candidate based on the company’s versatile Vaxiclase platform. Vaxiclase is a technology platform that can be used with many antigens in several […]

June 2, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 2 Jun 2015

Immuno-oncology race gets bloodier: BMS is suing its former executive now working for AstraZeneca

Immuno-oncology has gone from a competition to a battlefield. Bristol-Meyer Squibb launched a lawsuit against David Berman, a former researcher that abruptly quit last month after 10 years working for the company’s cancer R&D division. Berman, with his deep knowledge about BMS’s immune-oncology research, headed to AstraZeneca, BMS’ principal opponent. Game on. In this competitive […]

June 2, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Jun 2015

DNA Therapeutics presents positive results for its breakthrough Advanced Cancer Therapy

ASCO Annual Meeting keeps bringing positive results of European companies that cross the ocean to present their clinical trial outcomes. DNA Therapeutics, the French biopharma, presented the results of the first-in-man phase I/IIa trial of DT01 in patients with cutaneous metastatic melanoma. Cancer cells can easily repair themselves after damage incurred in their DNA from […]

June 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Jun 2015

Eisai receives Europe’s OK for its Thyroid Cancer treatment

Lenvatinib, Eisai’s treatment of thyroid cancer, has received the marketing authorization of the European Commission. The Japanese company is increasing its European presence with Lenvatinib, an orally administered molecular-targeted agent. Lenvatinib, commercially sold under the name Lenvima, is a designated orphan drug in Japan, the United States and in Europe for the treatment of people with […]

June 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 31 May 2015

AstraZeneca and Eli Lilly Combine their Innovative Drugs for Cancer Treatment

The big pharma companies Eli Lilly and AstraZeneca will combine two of their cancer drugs to make the perfect cocktail against solid tumors. They have entered a clinical collaboration to evaluate the safety and preliminary efficacy of AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor (MEDI4736), in combination with Cyramza (ramucirumab), Lilly’s VEGF Receptor 2 antiangiogenic cancer medicine. MEDI4736 is […]

May 31, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 31 May 2015

Who are the European Cancer Champions?

Cancer makes no difference… Children, elderly, healthy, disabled, black, white, etc… the disease randomly selects its targets. One of the biggest challenges of the Biotech industry today, is to lead groundbreaking innovations capable of treating cancer, which also encompass each individual’s biological specificity. So who are the leading champions? Recently, Thomson Reuters listed the 5 […]

May 31, 2015 - 2 minutesmins - By Alexandre Lowrey

News and Trends 25 May 2015

Invectys focuses on Telomers to develop a Universal Cancer Vaccine

French startup Invectys believes to have found the solution to cancer: one vaccine to cure them all! By targeting telomerase, this new immunotherapy could theoretically fight 95 % of all human cancers. When a cell divides, a small piece of DNA, called telomere, is lost at both ends of each chromosome. Telomerase adds these pieces of DNA again at the end of […]

May 25, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 22 May 2015

Fluorescent antibodies to guide Cancer surgery

French oncologist SurgiMab has started a first-in-human phase I study for its molecule SGM-101 launched at the Montpellier Cancer Institute. SurgiMab is developing antibody-fluorochrome conjugates to be used as in vivo diagnostic agents in oncology. SGM-101 is a fluorescent conjugate that consists on a tumor-specific monoclonal antibody and a near-infrared emitting fluorochrome. Thanks to this conjugate, oncology surgeons will […]

May 22, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 21 May 2015

The most effective Test for Ovarian Cancer raised €7.4M

Cancer is a devastating disease and, despite all the best efforts to develop new personalized medicines, too many lives end every year because of it. However, this trend might be about to change, after the latest study from University College London, published in the Journal of Clinical Oncology last week. The study highlighted that ROCA, […]

May 21, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 20 May 2015

Ipsen acquired OctreoPharm to strengthen its Oncology presence

Ipsen is determined to increase its presence in the oncology field, by acquiring OctreoPharm Sciences. The German life sciences company is focused on the development of radioactive labeled compounds for molecular imaging diagnostics and therapeutic applications. OctreoPharm’s shareholders are eligible to receive up to a total of approximately €50M for the purchase of 100% of […]

May 20, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 19 May 2015

PsiOxus raised €34.7 Million from First-Class investors

PsiOxus Therapeutics has closed a Series C financing round of €34.7M (£25 million) to progress its lead clinical candidate, enadenotucirev, and a pipeline of follow-on oncolytic programmes. Neil Woodford’s fund, GlaxoSmithKline’s VC unit and Imperial Innovations from Imperial College of London, amongst others, are behind the financing. PsiOxus’ lead product, enadenotucirev, is an oncolytic virus that, […]

May 19, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Erytech successfully completed its Phase III to ‘starve’ cancer cells to death

Genticel aims to prevent Cancer caused by the Human Papillomavirus

Immuno-oncology race gets bloodier: BMS is suing its former executive now working for AstraZeneca

DNA Therapeutics presents positive results for its breakthrough Advanced Cancer Therapy

Eisai receives Europe’s OK for its Thyroid Cancer treatment

AstraZeneca and Eli Lilly Combine their Innovative Drugs for Cancer Treatment

Who are the European Cancer Champions?

Invectys focuses on Telomers to develop a Universal Cancer Vaccine

Fluorescent antibodies to guide Cancer surgery

The most effective Test for Ovarian Cancer raised €7.4M

Ipsen acquired OctreoPharm to strengthen its Oncology presence

PsiOxus raised €34.7 Million from First-Class investors

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!